Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 9/20 | 0.77 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27163079 | 0.98 | IL4I1 (0.74) | IL4I1RXFP1HRH3POLBTP53 | |
| SCHEMBL30948085 | 0.89 | IL4I1 (0.78) | IL4I1RXFP1HRH3TP53LMNA | |
| SCHEMBL30948225 | 0.88 | IL4I1 (0.62) | IL4I1RXFP1HRH3POLBTP53 | |
| SCHEMBL30947971 | 0.88 | IL4I1 (0.61) | IL4I1RXFP1HRH3POLBTP53 | |
| SCHEMBL30948276 | 0.87 | IL4I1 (1.00) | IL4I1RXFP1HRH3TP53LMNA | |
| SCHEMBL30948332 | 0.87 | IL4I1 (0.71) | IL4I1RXFP1HRH3POLBTP53 | |
| SCHEMBL30948159 | 0.87 | IL4I1 (0.74) | IL4I1RXFP1HRH3TP53LMNA | |
| SCHEMBL30947910 | 0.87 | IL4I1 (0.60) | IL4I1HRH3ACHE | |
| SCHEMBL30947926 | 0.87 | IL4I1 (0.63) | IL4I1RXFP1HRH3POLBTP53 | |
| SCHEMBL30948340 | 0.87 | IL4I1 (0.60) | IL4I1RXFP1HRH3POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4329889-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022227015-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022232333-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | IL4I1 1/4885RXFP1 1354/4885HRH3 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.